X-RAY AND MOLECULAR IMAGING DURING PREGNANCY AND BREASTFEEDING—WHEN SHOULD WE BE WORRIED?
-
- Sören Mattsson
- Medical Radiation Physics Malmö, Department of Translational Medicine, Lund University, Malmö, SE-205 02 Malmö, Sweden
-
- Sigrid Leide-Svegborn
- Medical Radiation Physics Malmö, Department of Translational Medicine, Lund University, Malmö, SE-205 02 Malmö, Sweden
-
- Martin Andersson
- Medical Radiation Physics Malmö, Department of Translational Medicine, Lund University, Malmö, SE-205 02 Malmö, Sweden
この論文をさがす
説明
<jats:title>Abstract</jats:title><jats:p>Some of the ethically most sensitive issues in radiation protection arise at imaging of pregnant—and potentially pregnant—patients and of newborn.</jats:p><jats:p>This article reviews the current literature and recommendations on imaging during pregnancy and breastfeeding. Risks related to alternative non-ionizing radiation methods are also considered.</jats:p><jats:p>With few exceptions, exposure of the fetus through radiography, computed tomography (CT) and nuclear medicine imaging can be limited to safe levels, although studies such as abdominal-pelvic CT cannot avoid significant exposure to fetuses. Eight to 10 weeks post-conception, the fetus has a thyroid which starts to concentrate iodide having crossed the placenta barrier resulting in unacceptably high doses to the fetal thyroid after administration of 131I- and even 123I-iodide and other radiopharmaceuticals with a high content of free radioiodine.</jats:p><jats:p>Many radiopharmaceuticals are excreted through breast milk. Breastfeeding interruption recommendations should be followed to keep the effective dose to the infant below 1 mSv.</jats:p>
収録刊行物
-
- Radiation Protection Dosimetry
-
Radiation Protection Dosimetry 195 (3-4), 339-348, 2021-04-14
Oxford University Press (OUP)
